Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome
- PMID: 10443656
- DOI: 10.1210/jcem.84.8.5884
Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome
Abstract
Although FSH is essential to stimulate ovarian folliculogenesis, increasing physiological and clinical evidence suggests that moderate LH stimulation may also be critical for optimal follicle and oocyte development. Conversely, a clinical trend exists toward conducting controlled ovarian hyperstimulation (COH) in a LH-depleted environment, as recently developed gonadotropin preparations are devoid of LH activity, and endogenous LH is suppressed with GnRH analogs in most COH cycles. To investigate the role of LH activity during COH we supplemented highly purified (HP) FSH with low dose hCG in GnRH agonist-suppressed women. Twenty normoovulatory women were pretreated with a GnRH agonist and after 2 weeks were randomly assigned to receive HP FSH (150 IU/day) alone (group A; 10 patients) or combined with hCG (50 IU/day; group B; 10 patients). The HP FSH dose was increased after 14 days only in cases of inadequate response. Treatment was monitored with pelvic ultrasound and daily hormone determinations. None of the patients of group B and 8 of group A required more than 14 days of treatment and increments of the FSH dose. Folliculogenesis and 17beta-estradiol (E2) secretion progressed more rapidly and evenly in group B. Although preovulatory follicle number and E2 concentrations were comparable, patients in group B required a shorter stimulation time (12.5+/-0.6 vs. 17.3+/-0.7 days in group A; P < 0.0001) and a lower HP FSH dose (1725+/-84 vs. 2670+/-164 IU in group A; P < 0.0001). Serum levels of LH, E2, progesterone, and testosterone did not differ between the 2 groups; serum FSH was higher in group A. We conclude that LH activity promotes folliculogenesis in synergy with FSH in the mid- to late follicular phase and that low dose hCG coadministration optimizes COH by 1) enhancing FSH action, 2) accelerating ovarian follicle development, 3) shortening COH duration, 4) lowering HP FSH requirements, and 5) reducing COH cost. Thus, moderate LH activity in the follicular phase plays a positive physiological and clinical role in folliculogenesis and ovulation induction.
Similar articles
-
Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation.J Clin Endocrinol Metab. 2001 Jan;86(1):337-43. doi: 10.1210/jcem.86.1.7108. J Clin Endocrinol Metab. 2001. PMID: 11232021 Clinical Trial.
-
Stimulation and growth of antral ovarian follicles by selective LH activity administration in women.J Clin Endocrinol Metab. 2002 Mar;87(3):1156-61. doi: 10.1210/jcem.87.3.8322. J Clin Endocrinol Metab. 2002. PMID: 11889180
-
The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development.J Clin Endocrinol Metab. 1998 Apr;83(4):1292-8. doi: 10.1210/jcem.83.4.4710. J Clin Endocrinol Metab. 1998. PMID: 9543158 Clinical Trial.
-
Outlook: who needs LH in ovarian stimulation?Reprod Biomed Online. 2006 May;12(5):599-607. doi: 10.1016/s1472-6483(10)61186-8. Reprod Biomed Online. 2006. PMID: 16790105 Review.
-
Clinical review 126: Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction.J Clin Endocrinol Metab. 2001 Apr;86(4):1437-41. doi: 10.1210/jcem.86.4.7385. J Clin Endocrinol Metab. 2001. PMID: 11297565 Review.
Cited by
-
Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations.Int J Mol Sci. 2024 Aug 29;25(17):9405. doi: 10.3390/ijms25179405. Int J Mol Sci. 2024. PMID: 39273352 Free PMC article.
-
Randomized, Controlled Pilot Study of Low-Dose Human Chorionic Gonadotropin Administration Beginning From the Early Follicular Phase for Women With Polycystic Ovarian Syndrome Undergoing Ovarian Stimulation Using the Progesterone Protocol.Front Endocrinol (Lausanne). 2019 Dec 13;10:875. doi: 10.3389/fendo.2019.00875. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31920984 Free PMC article.
-
The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.J Ovarian Res. 2022 Jun 21;15(1):74. doi: 10.1186/s13048-022-01009-w. J Ovarian Res. 2022. PMID: 35729654 Free PMC article.
-
Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial.Iran J Reprod Med. 2014 Feb;12(2):111-6. Iran J Reprod Med. 2014. PMID: 24799868 Free PMC article.
-
Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins.Reprod Biol Endocrinol. 2014 Dec 28;12:128. doi: 10.1186/1477-7827-12-128. Reprod Biol Endocrinol. 2014. PMID: 25543693 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous